We are live on ! Find out more
RAPT icon

RAPT Therapeutics

Delisted

RAPT was delisted on the 2nd of March, 2026.

50 hedge funds and large institutions have $136M invested in RAPT Therapeutics in 2025 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 34 reducing their positions, and 45 closing their positions.

New
Increased
Maintained
Reduced
Closed

152% more call options, than puts

Call options by funds: $295K | Put options by funds: $117K

33% more capital inflows, than outflows

Capital inflows: $15.6M | Capital outflows: $11.7M

3.23% more ownership

Funds ownership: 99.34% → 102.57% (+3.2%)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

46% less funds holding

Funds holding: 92 → 50 (-42)

74% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 34

91% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 45

Holders
50
Holders Change
-42
Holders Change %
-45.65%
% of All Funds
0.65%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
4
Increased
9
Reduced
34
Closed
45
Calls
$295​K
Puts
$117​K
Net Calls
+$178​K
Net Calls Change
+$117​K

RAPT Hedge Fund Activity: Q2 2025 in Review

50 of the 7,634 institutional investors tracked by Wall St. Rank reported a position in RAPT Therapeutics (RAPT) for Q2 2025, worth a combined $136M — down 15% from $160M a quarter earlier.

Sellers outnumbered buyers: 45 funds closed out of RAPT and 4 opened new positions — a net loss of 41 holders — while 34 trimmed existing stakes and 9 added.

The largest buyer was Column Group, adding an estimated $8.87M. The largest seller was Perceptive Advisors, cutting an estimated $2.81M.

  • 50 institutional investors held RAPT Therapeutics (RAPT) as of Q2 2025, down from 92 in Q1 2025.
  • Funds reported $136M of RAPT Therapeutics stock for Q2 2025, down 15% quarter-over-quarter.
  • 4 funds opened new RAPT Therapeutics positions in Q2 2025 and 45 closed out, a net change of -41 holders.
  • The largest RAPT Therapeutics buyer in Q2 2025 was Column Group, an estimated $8.87M added.
  • The largest RAPT Therapeutics seller in Q2 2025 was Perceptive Advisors, an estimated $2.81M sold.

Based on aggregated 13F filings for Q2 2025.